{
    "code": "52028481",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52028481",
    "time": "2024-04-04 19:56:56",
    "許可證字號": "衛部藥輸字第028481號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "117\/05\/16",
    "發證\/登錄日期": "112\/05\/16",
    "許可證\/登錄種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05202848102",
    "中文品名": "癌沛特&quot;山德士&quot;25毫克\/毫升注射劑",
    "英文品名": "Pemetrexed Sandoz 25mg\/mL Concentrate for solution for Infusion",
    "適應症": "1.併用cisplatin是治療局部晚期或轉移性非小細胞肺癌（顯著鱗狀細胞組織型除外）之第一線化療用藥。2.單一藥物是局部晚期或轉移性非小細胞肺癌（顯著鱗狀細胞組織型除外）病人接受4個週期含鉑藥物的第一線化療後疾病並未惡化之維持療法。3.單一藥物是治療局部晚期或轉移性非小細胞肺癌（顯著鱗狀細胞組織型除外）之第二線治療用藥。4.與pembrolizumab及含鉑化學療法併用，做為轉移性，不具有EGFR或ALK腫瘤基因異常之非鱗狀非小細胞肺癌的第一線治療藥物。5.與cisplatin併用於治療惡性肋膜間質細胞瘤。",
    "劑型": "270注射劑",
    "包裝": "100毫克\/4毫升、500毫克\/20毫升玻璃小瓶裝 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "監視期滿學名藥;",
    "監視期限": "",
    "主成分略述": "Pemetrexed disodium 2.5 hydrate",
    "限制項目": "02輸　入 24監視期滿學名藥",
    "申請商名稱": "台灣山德士藥業股份有限公司",
    "申請商地址": "臺北市中山區民生東路3段2號8樓",
    "主製造廠": [
        {
            "製造廠名稱": "FAREVA Unterach GmbH",
            "製造廠廠址": "MONDSEESTRASSE 11, 4866 UNTERACH AM ATTERSEE, AUSTRIA",
            "製造廠公司地址": "",
            "製造廠國別": "AUSTRIA",
            "製程": ""
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1004002420",
            "成分名稱": "Pemetrexed disodium 2.5 hydrate",
            "含量描述": "Pemetrexed....25mg (Pemetrexed Disodium 2.5 hydrate....30.2mg)",
            "含量": "25.0000000000",
            "單位": "MG"
        }
    ]
}